<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962611</url>
  </required_header>
  <id_info>
    <org_study_id>12871</org_study_id>
    <nct_id>NCT00962611</nct_id>
  </id_info>
  <brief_title>BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer</brief_title>
  <official_title>An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability, maximum tolerated dose and
      pharmacokinetics of this drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2009</start_date>
  <completion_date type="Actual">February 23, 2016</completion_date>
  <primary_completion_date type="Actual">February 23, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate for early signs of efficacy in expansion cohorts</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Copanlisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (Aliqopa, BAY80-6946)</intervention_name>
    <description>BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.</description>
    <arm_group_label>Copanlisib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years.

          -  Histological or cytological documentation of non-hematologic, malignant solid tumor,
             excluding primary brain or spinal tumors, or history of central nervous system
             metastases

          -  At least one measurable lesion or evaluable disease

          -  Life expectancy of at least 12 weeks

          -  ECOG Performance Status of 0, 1 or 2

          -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically
             anticoagulated with an agent such as coumadin or heparin will be allowed to
             participate provided that no prior evidence of underlying abnormality in these
             parameters exists]. Low-dose aspirin is permitted (&lt;/= 100 mg daily).

          -  Adequate bone marrow, liver and renal function

          -  Ability to understand and to sign an informed consent form; a signed informed consent
             must be obtained prior to any study specific procedures

        Exclusion Criteria:

          -  History of cardiac disease congestive heart failure (CHF) &gt; NYHA Class II; active
             coronary artery disease, myocardial infarction within 6 months prior to study entry;
             new onset angina within 3 months prior to study entry or unstable angina or cardiac
             arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are
             permitted).

          -  Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level
             &gt;125 mg/dL at screening, or HbA1c 7%

          -  Active clinically serious infections &gt; Grade 2 (NCI-CTCAE Version 3.0)

          -  History of having received allogeneic organ transplant

          -  Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic
             drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire
             study.

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg, despite optimal medical management
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <reference>
    <citation>A. Patnaik et al. Supplementary materials /Supplementary methods. Annals of Oncology 2016</citation>
  </reference>
  <results_reference>
    <citation>Rowe EL. Automated drop volume apparatus for surface tension measurement. J Pharm Sci. 1972 May;61(5):781-2.</citation>
    <PMID>5035790</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Advanced cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

